Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
|Articles|July 20, 2020
Contact BioPharm International Editors
Listen
0:00 / 0:00
Key Takeaways
- BioPharm International's editorial team includes key figures like Christopher Cole and Susan Haigney, with specific contact details provided for communication.
- Contributing editors such as Cynthia A. Challener, PhD, and Siegfried Schmitt offer specialized expertise, enhancing the publication's content.
View contact information for the BioPharm International editorial team.
Advertisement
BioPharm International Editors
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831
United States
Press Release and News Announcements
Send press releases to
Article/Submission Inquiries
Editorial Staff
Christopher Cole
Associate Editorial Director
Susan Haigney
Lead Editor
tel. 732.346.3045
Feliza Mirasol
Science Editor
tel. 732.346.3024
Patrick Lavery
Editor
tel. 609.716.7777
Contributing Editors/Columnists
Cynthia A. Challener, PhD
Contributing Editor
Siegfried Schmitt
Ask the Expert
Susan J. Schniepp
Ask the Expert
Subscription Support
Advertisement
Related to this article
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Ivonescimab, in phase 3 trials across 8 tumor types, will be paired with sonesitatug vedotin in new gastrointestinal cancer trials.
Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Advertisement
Advertisement